Business Wire

NY-AQARA

23.3.2023 09:01:30 CET | Business Wire | Press release

Share
Aqara Releases Video Doorbell G4 with Facial Recognition to Global Markets

Aqara, a leading provider of smart home products, announces the wide availability of the Company’s first smart video doorbell, the G4, on global markets. This 1080p doorbell features wide compatibility with third-party smart home platforms such as Apple Home, Alexa and Google Home, and it is equipped with on-device AI to enable local facial recognition alerts and automation. Together with the Company’s indoor cameras, the video doorbell G4 helps users keep an eye on their homes, families and visitors anytime, anywhere. The device is now available on Aqara’s Amazon brand stores in both North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK) as well as via selective Aqara retailers worldwide1.

Similar to Aqara’s Camera Hub G3, the Aqara Smart Video Doorbell G4 features AI-based facial recognition, which is executed locally on device for faster response and privacy protection. Moreover, facial recognition of the doorbell can be used as an automation trigger, allowing users to set up customized home automation for different families and visitors. For example, the welcome home scene will be activated when the G4 recognizes a family member coming home. Or in the case that it detects the postman, the doorbell will play a pre-recorded message. When connected to other Aqara devices, the G4 doorbell can also be a strong addition to the Aqara Home alert system as it not only monitors the activities around the front porch but also lets out a loud siren in case of home intrusion and other emergencies.

Apart from the Aqara ecosystem, the G4 doorbell also supports major third-party smart home platforms including Apple Home, Amazon Alexa and Google Home. This device is one of the few battery-powered video doorbells on the market that support Apple’s HomeKit Secure Video as well as the local streaming to Amazon and Google smart displays. Moreover, Aqara anticipates adding the support of the new Matter standard to the G4 via a future OTA (over the air) update2.

With two color variants, Shadow Gray and Black, the video doorbell G4 is designed to fit into most home environments. It supports both wireless and wired installation and can use a pack of 6 AA batteries that lasts about 4 months3. The doorbell offers adjustable sensitivity, configurable motion detection and even a power saving mode for users who live in a high traffic area to extend the battery life. Alternatively, users can opt to wire the G4 doorbell to an AC/DC transformer for 24/7 recording4, and use the battery pack as a back-up power source. Additionally, the G4’s chime repeater, which is equipped with a 95 dB speaker, houses a Type-C port, and allows more flexibility for users to place the chime repeater indoors.

Users of the Video Doorbell G4 can store video footage locally or on the cloud via iCloud or Aqara platform5. Aqara offers a subscription-free cloud storage of up to 7 days of critical event clips such as motion detection, facial recognition, doorbell ring and tamper alerts. Users can also choose to save video footage locally using a microSD card (up to 512 GB)6, which is housed in the indoor chime repeater. Finally, videos can also be stored via SMB NAS for added flexibility and security7.

For more details of the G4 video doorbell, please visit our website.

  1. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
  2. Matter support is not available by the time of launch.
  3. Based on assumption of 35 device wake-ups and one 6-second event video recording per day. The actual battery life may vary, depending on multiple factors including device usage, battery capacity, ambient temperature, etc.
  4. A 12-24V AC or 8-24V DC transformer is required. Both a wired installation and the use of a microSD card are required for 24/7 recording.
  5. iCloud or other supported cloud storage is not included, and should be controlled separately via the respecting app.
  6. The microSD card is not included.
  7. SMB NAS support may be unavailable by the time of product launch.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005016/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye